Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.62 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.50 |
| ▸ | TYMS | P04818 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733162 | 0.84 | ESR1 (0.51) | ESR1ESR2NR1H3TYMSNR1H2 | |
| SCHEMBL19950447 | 0.82 | CYP3A4 (0.61) | ESR1ESR2NR1H3TYMSNR1H2 | |
| SCHEMBL8079827 | 0.82 | ESR1 (0.72) | ESR1ESR2NR1H3ANPEPDPP4 | |
| SCHEMBL30268221 | 0.81 | TYMS (0.72) | ESR1ESR2NR1H3TYMSHSP90AA1 | |
| SCHEMBL2150841 | 0.80 | MEN1 (0.55) | ESR1ESR2NR1H3NR1H2PIM3 | |
| SCHEMBL3435311 | 0.79 | CYP3A4 (0.66) | ESR1ESR2NR1H3NR1H2MEN1 | |
| SCHEMBL17200427 | 0.77 | LMNA (0.50) | ESR1ESR2NR1H3TYMSNR1H2 | |
| SCHEMBL23133322 | 0.76 | TYMS (0.43) | ESR1ESR2NR1H3TYMSHSP90AA1 | |
| SCHEMBL8585931 | 0.75 | POLB (0.68) | ESR1ESR2NR1H3ANPEPDPP4 | |
| SCHEMBL27250012 | 0.74 | TYMS (0.44) | ESR1ESR2NR1H3TYMSHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567411-A | Polyimide dianhydride monomer capable of realizing bidirectional polymerization and synthesis method thereof | 仪征市海帆化工有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-117247367-A | Novel polyimide dianhydride monomer and synthesis method thereof | 邹从伟 | 2023-12-19 | — | — | CN | claimed |
| CN-117567411-A | Polyimide dianhydride monomer capable of realizing bidirectional polymerization and synthesis method thereof | 仪征市海帆化工有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117567411-A | Polyimide dianhydride monomer capable of realizing bidirectional polymerization and synthesis method thereof | 仪征市海帆化工有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117247367-A | Novel polyimide dianhydride monomer and synthesis method thereof | 邹从伟 | 2023-12-19 | — | — | CN | disclosed |
| CN-117247367-A | Novel polyimide dianhydride monomer and synthesis method thereof | 邹从伟 | 2023-12-19 | — | — | CN | disclosed |
| EP-1682555-A1 | MACROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050215556-A1 | Macrocyclic kinase inhibitors | ABBVIE INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005047294-A1 | MACROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215556-A1 | Macrocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K7 | ESR1 3362/4885ESR2 2051/4885NR1H3 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.